Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.

Abbott RA, Acland KM, Harries M, O'Doherty M.

Melanoma Res. 2011 Oct;21(5):446-9. doi: 10.1097/CMR.0b013e3283480256.

PMID:
21849913
2.

Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma.

Koskivuo I, Kemppainen J, Giordano S, Seppänen M, Veräjänkorva E, Vihinen P, Minn H.

Acta Oncol. 2016 Nov;55(11):1355-1359. Epub 2016 Aug 24.

PMID:
27553064
3.

Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.

Gellén E, Sántha O, Janka E, Juhász I, Péter Z, Erdei I, Lukács R, Fedinecz N, Galuska L, Remenyik É, Emri G.

J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1938-44. doi: 10.1111/jdv.13084. Epub 2015 Mar 9.

PMID:
25753249
4.

Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.

Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.

Interact Cardiovasc Thorac Surg. 2010 Jun;10(6):1009-14. doi: 10.1510/icvts.2009.227538. Epub 2010 Mar 2.

PMID:
20197344
5.

FDG PET in early stage cutaneous malignant melanoma.

McIvor J, Siew T, Campbell A, McCarthy M.

J Med Imaging Radiat Oncol. 2014 Apr;58(2):149-54; quiz 266. doi: 10.1111/1754-9485.12173.

PMID:
24690243
6.

Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit.

Constantinidou A, Hofman M, O'Doherty M, Acland KM, Healy C, Harries M.

Melanoma Res. 2008 Feb;18(1):56-60. doi: 10.1097/CMR.0b013e3282f62404.

PMID:
18227709
7.

Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.

Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.

PLoS One. 2014 Dec 17;9(12):e115127. doi: 10.1371/journal.pone.0115127. eCollection 2014.

8.

[(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) physiologic imaging of choroidal melanoma: before and after ophthalmic plaque radiation therapy.

Finger PT, Chin KJ.

Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):137-42. doi: 10.1016/j.ijrobp.2009.10.041. Epub 2010 Apr 13.

PMID:
20395070
9.

F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.

Schröer-Günther MA, Wolff RF, Westwood ME, Scheibler FJ, Schürmann C, Baumert BG, Sauerland S, Kleijnen J.

Syst Rev. 2012 Dec 13;1:62. doi: 10.1186/2046-4053-1-62. Review.

10.

18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.

Toba H, Sakiyama S, Otsuka H, Kawakami Y, Takizawa H, Kenzaki K, Kondo K, Tangoku A.

Interact Cardiovasc Thorac Surg. 2012 Nov;15(5):859-64. doi: 10.1093/icvts/ivs368. Epub 2012 Aug 21.

11.

Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma.

Baker JJ, Meyers MO, Frank J, Amos KD, Stitzenberg KB, Ollila DW.

Am J Surg. 2014 Apr;207(4):549-54. doi: 10.1016/j.amjsurg.2013.04.012.

PMID:
24674829
12.

Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.

Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, Roedel R, Strunk H, Bieber T, Biersack HJ, Tüting T.

J Clin Oncol. 2006 Mar 1;24(7):1178-87.

PMID:
16505438
13.

A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.

Beasley GM, Parsons C, Broadwater G, Selim MA, Marzban S, Abernethy AP, Salama AK, Eikman EA, Wong T, Zager JS, Tyler DS.

Ann Surg. 2012 Aug;256(2):350-6. doi: 10.1097/SLA.0b013e318256d1f5.

14.

Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.

Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ 3rd, Hutchins G, Love C, Wenck S, Daggy J.

Cancer. 2005 Aug 1;104(3):570-9.

15.

PET/Computed Tomography and Patient Outcomes in Melanoma.

Rohren EM.

PET Clin. 2015 Apr;10(2):243-54. doi: 10.1016/j.cpet.2014.12.006. Epub 2015 Feb 21. Review.

PMID:
25829089
16.

Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.

Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.

Nucl Med Commun. 2012 Jun;33(6):591-6. doi: 10.1097/MNM.0b013e3283516716.

PMID:
22334135
17.

Clinical use of positron emission tomography in the management of cutaneous melanoma.

Friedman KP, Wahl RL.

Semin Nucl Med. 2004 Oct;34(4):242-53. Review.

PMID:
15493002
18.

18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.

Mena E, Taghipour M, Sheikhbahaei S, Mirpour S, Xiao J, Subramaniam RM.

Clin Nucl Med. 2016 Sep;41(9):e403-9. doi: 10.1097/RLU.0000000000001275.

PMID:
27355846
19.

Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.

Mansour AA 3rd, Kelley MC, Hatmaker AR, Holt GE, Schwartz HS.

Ann Surg Oncol. 2010 Apr;17(4):1144-51. doi: 10.1245/s10434-009-0843-4. Epub 2009 Dec 5.

PMID:
19967460
20.

Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.

Wagner T, Meyer N, Zerdoud S, Julian A, Chevreau C, Payoux P, Courbon F.

Br J Dermatol. 2011 Jun;164(6):1235-40. doi: 10.1111/j.1365-2133.2011.10247.x. Epub 2011 May 13.

PMID:
21332457

Supplemental Content

Support Center